Neoplasms

Symptoms and General Pathology

All Conditions

Neoplasm Metastasis

Neoplasms, Second Primary

Neoplastic Processes

Participants are assigned to Group 1, participants will be treated with next-line systemic therapy. The specific next-line systemic therapy will be determined by your doctor.

- If progression occurs (the disease gets worse), participants may cross over to Group 2 and receive LCT.

Participants are assigned to Group 2, participants will be treated with LCT and then continue on same systemic therapy participants have been receiving followed by the next line systemic of therapy (if applicable). The specific treatments will be determined by your doctor.

Participants may receive radiation therapy. The choice of LCT and radiation therapy regimen will be determined by a multidisciplinary team including the study doctor.

Local Consolidation Therapy

The specific next-line systemic therapy will be determined by your doctor.

Next-line Systemic Therapy

Ethan Ludmir, MD

Ethan Ludmir

To find out if local consolidation therapy (such as radiation therapy with or without other local therapies such as surgery, ablation \[the removal or destruction of a body part or tissue or its function\], or embolization \[a procedure that uses particles, such as tiny gelatin sponges or beads, to block a blood vessel\]) to all progressive sites of disease can help to control the disease compared with next-line systemic therapy.

Primary Objective:

• To determine whether, in participants with oligoprogressive metastatic disease, LCT to all progressive sites of disease offers a benefit in PFS compared to NLST, across seven tumor types in a basket design.

Secondary Objectives:

* To determine whether LCT improves OS in participants with oligoprogressive disease across seven tumor types.
* To assess safety/tolerability of LCT in participants with oligometastatic disease in tumor subtypes.
* To compare quality of life (QOL) of LCT vs. next-line systemic therapy in participants with oligoprogressive disease.
* To characterize duration and progression-free survival time of participants on same-line systemic therapy (SLST) after LCT in the experimental arm.
* To identify predictive/prognostic biomarkers correlated with a benefit for LCT across tumor types, with the aim being to incorporate these biomarkers into future clinical trials.

A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)	NCT06367972	OligoProgressiv...	Local Consolida... Next-line Syste...	18 Years -	M.D. Anderson Cancer Center
A Randomized Phase II Basket Trial EXTENDing Efficacy of Systemic Therapy With Local Consolidative Therapy for OligoProgressive Metastatic Disease (EXTEND-OP)	NCT06367972	OligoProgressiv...	Local Consolida... Next-line Syste...	18 Years -	M.D. Anderson Cancer Center

Spots Global Cancer Trial Database for oligoprogressive metastatic disease